Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 9 von 71

Details

Autor(en) / Beteiligte
Titel
The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study
Ist Teil von
  • International journal of gynecological pathology, 2009-01, Vol.28 (1), p.35-40
Ort / Verlag
United States
Erscheinungsjahr
2009
Quelle
MEDLINE
Beschreibungen/Notizen
  • To evaluate if morphometric features (mitotic activity index, volume percentage of epithelium, and DNA ploidy) are prognostic markers in borderline ovarian tumors (BOTs). Ninety-three serous and mucinous consecutive BOTs diagnosed between 1989 and 2002 were studied. In all tumors, mitotic activity index, volume percentage of epithelium, and DNA ploidy were determined prospectively. Consecutively, age at diagnosis, calculated tumor volume, International Federation of Gynecology and Obstetrics (FIGO) stage, and treatment by extensive staging were evaluated after a median follow-up of 52 months. Serous BOTs presented at a younger age (P<0.05), with smaller volume (P<0.001), with higher FIGO stage (P<0.001), and were more frequently bilateral (P<0.001) than mucinous BOTs. Patients with serous BOT (P<0.05) and beyond stage Ia (P<0.01) showed worse recurrence-free survival. No prognostic significance could be established for DNA ploidy or morphometry. The previously claimed prognostic power of DNA ploidy and morphometry could not be corroborated in this prospective study and can therefore not be recommended to direct clinical management in BOTs. In contrast, histologic subtype and FIGO stage seem to be stable prognosticators in BOTs.
Sprache
Englisch
Identifikatoren
ISSN: 0277-1691
eISSN: 1538-7151
DOI: 10.1097/PGP.0b013e31818131ff
Titel-ID: cdi_crossref_primary_10_1097_PGP_0b013e31818131ff

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX